All In Biotech

Drug Trial Radar · NCT07899996

A Study of HB0056 in Adult Participants With Moderate to Severe Asthma

A Randomized, Double-blind, Placebo-controlled Phase Ib/II Study to Evaluate the Efficacy and Safety of HB0056 in Adult Participants With Moderate to Severe Asthma

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Aug 21, 2025

Primary completion

Aug 1, 2027

Study completion Aug 1, 2028

Sponsor

Sponsor type
Industry
First posted
Oct 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if drug HB0056 works to treat severe asthma in adults. It will also learn about the safety of drugHB0056. The main questions it aims to answer are: Does drug HB0056 lower the number of times participants need to use a rescue inhaler? What medical problems do participants have when taking drug HB0056? Researchers will compare drug HB0056 to a placebo to see if drug HB0056 works to treat severe asthma. Participants will: Take drug HB0056 or a placebo Q2W. Keep a diary of their symptoms and the number of times they use a rescue inhaler

Conditions

  • Asthma

Interventions

  • PlaceboDrug

    Placebo

  • HB0056Drug

    Targeting TSLP and IL-11 IgG1-type Bispecific Antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part I(Phase Ib): AEsTime frame: From baseline to week 16
  2. Part I (Phase Ib): Tss_maxTime frame: From baseline to week 16
  3. Part II (Phase II): Change from baseline in pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1)Time frame: From baseline to week 12

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • China-Japan Friendship Hospital

    Beijing, China · Recruiting

  • China-Japan Friendship Hospital

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.